Teva Pharmaceuticals swung to a loss on an acquisition write-down, as its interim CEO contends with a deal-driven debt load, though shares rose as the company beat revenue and profit expectations.
from WSJ.com: US Business http://ift.tt/2l2gKHe
via IFTTT
No comments:
Post a Comment